Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans
Hartter E, Svoboda T, Ludvik B et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34: 52-54.
Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control
Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7: 1353-1373.
AstraZeneca Pharmaceuticals LP. Symlin® (pramlintide acetate) injection - prescribing information (revised February ). Available from URL:. Accessed 19 March 2015.
AstraZeneca Pharmaceuticals LP. Symlin® (pramlintide acetate) injection - prescribing information (revised February 2015). Available from URL: http://www.azpicentral.com/symlin/pi_symlin.pdf#page=1. Accessed 19 March 2015.
(2015)
5
8144228619
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial
Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004; 21: 1204-1212.
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25: 724-730.
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study
Weyer C, Gottlieb A, Kim DD et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 2003; 26: 3074-3079.
Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies
Bak MJ, Wewer Albrechtsen NJ, Pedersen J et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab 2014; 16: 1155-1164.
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes
Edelman S, Garg S, Frias J et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006; 29: 2189-2195.
In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes
Micheletto F, Dalla Man C, Kolterman O et al. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. Diabetes Technol Ther 2013; 15: 802-809.
